Abstract
Selective serotonin reuptake inhibitors (SSRIs) are becoming widely used because of their favorable side-effect profile and their safety in overdose. We report about a patient with recurring major depression (DSM-IIIR) who was treated with paroxetine and developed a severe hepatotoxic reaction, which was reversed after withdrawal of the drug. Individual, patient-related causes for this side-effect were not found. To our knowledge, this is the first published case of a probably paroxetine-induced severe hepatotoxicity. Hepatotoxicity should be taken into account as a rare complication that may occur not only with tricyclic antidepressants (TCAs) but also with SSRIs.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Pharmacopsychiatry |
| Jahrgang | 29 |
| Ausgabenummer | 6 |
| Seiten (von - bis) | 223-226 |
| Seitenumfang | 4 |
| ISSN | 0176-3679 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.01.1996 |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
-
SDG 9 – Industrie, Innovation und Infrastruktur
-
SDG 10 – Weniger Ungleichheiten
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)
Fingerprint
Untersuchen Sie die Forschungsthemen von „Reversible hepatotoxicity of paroxetine in a patient with major depression“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver